trial

Development and Application of Precision Treatment Strategies for Common Mental Disorders

NCTId NCT06729541
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 600 (estimated)
Sponsored by Peking University
Primary completion 2026-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
600 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2024-11-11
Primary completion
2026-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Multigenetic Pharmacogenomics-Guided Treatment (MPGT)

Sponsors

Peking UniversityLead Sponsor

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
600
Phase
NA
Primary Completion Date
2026-07
Status
RECRUITING
relationships
The graph out of here
drug
Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
drug
lead_sponsor
Peking University
company
indication
Bipolar Disorder
indication
Depression - Major Depressive Disorder
indication
Schizophrenia Disorders
indication